{
    "clinical_study": {
        "@rank": "88881", 
        "arm_group": [
            {
                "arm_group_label": "CHF 6001  SD or placebo", 
                "arm_group_type": "Experimental", 
                "description": "Single administration of CHF 6001 dose levels 1 to 7 or placebo"
            }, 
            {
                "arm_group_label": "CHF 6001 MD or placebo", 
                "arm_group_type": "Experimental", 
                "description": "Multiple administration of CHF 6001 dose levels 1 to 5 or placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to investigate the safety, tolerability and pharmacokinetics of\n      inhaled CHF 6001 after single and multiple doses in healthy volunteers."
        }, 
        "brief_title": "Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)", 
        "completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease (COPD)", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will be conducted in a single centre and will consist of a single dose part and a\n      multiple dose part.\n\n      Seven single doses of CHF 6001 will be administered according to an escalation, alternate\n      cross over scheme. Five multiple doses of CHF 6001 will be administered for 7 days according\n      to a sequential escalation scheme."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject's written informed consent obtained prior to any study-related procedure\n\n          -  Male healthy volunteers aged 18-55 years;\n\n          -  Able to understand the study procedures, the risks involved and ability to be trained\n             to use the devices correctly.\n\n          -  Body Mass Index (BMI) between 18.0 and 28.0 kg/m2;\n\n          -  Non- or ex-smokers who smoked < 5 pack years (pack-years = the number of cigarette\n             packs per day times the number of years) and stopped smoking > 1 year;\n\n          -  Results of laboratory tests within the normal ranges. Minor deviations are acceptable\n             provided that they are not judged clinically significant by the investigator.\n\n          -  A reliable method of contraception for the subjects and their partner.\n\n        Exclusion Criteria:\n\n          -  Blood donation or blood loss less than 8 weeks before inhalation of the study\n             medication;\n\n          -  Positive HIV1 or HIV2 serology;\n\n          -  Positive results from the Hepatitis serology which indicates acute or chronic\n             Hepatitis B or Hepatitis C;\n\n          -  History of substance abuse or drug abuse within 12 months prior to screening visit or\n             with a positive urine drug screen at screening;\n\n          -  Clinically relevant abnormal laboratory values suggesting an unknown disease and\n             requiring further clinical investigation;\n\n          -  Clinically significant and uncontrolled cardiac, hepatic, renal, gastrointestinal,\n             endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with\n             successful completion of this protocol;\n\n          -  Treatment within the previous 3 months with any drug known to have a well defined\n             potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole).\n\n          -  Subjects who refuse to abstain from alcohol or caffeine containing foods or beverages\n             or grapefruit containing foods or beverages from 48 hour prior to each intake of\n             study medication until the end of confinement at the clinical centre.\n\n          -  Heavy caffeine drinker (> 5 cups or glasses of caffeinated beverages e.g., coffee,\n             tea, cola per day)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703052", 
            "org_study_id": "CCD-1006-PR-0048"
        }, 
        "intervention": [
            {
                "arm_group_label": "CHF 6001  SD or placebo", 
                "description": "Dry Powder Inhaler", 
                "intervention_name": "CHF 6001 SD or placebo", 
                "intervention_type": "Drug", 
                "other_name": "CHF 6001 DPI"
            }, 
            {
                "arm_group_label": "CHF 6001 MD or placebo", 
                "description": "Dry Powder Inhaler", 
                "intervention_name": "CHF 6001 MD or placebo", 
                "intervention_type": "Drug", 
                "other_name": "CHF 6001 DPI"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 8, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nottingham", 
                    "country": "United Kingdom"
                }, 
                "name": "Quotient Clinical"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Placebo-controlled Double-blind Single and Repeated Ascending Dose Study to Investigate the Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Quotient Clinical", 
            "last_name": "Stuart Mair, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "The number and percentage of subjects with adverse events, adverse drug reactions, serious adverse events", 
                "measure": "Adverse events, adverse drug reactions, serious adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "After 7 days of treatment"
            }, 
            {
                "description": "Blood pressure and Heart rate", 
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "After 7 days of treatment"
            }, 
            {
                "description": "Heart rate, RR, PR, QRS, QT, QTcB, QTcF", 
                "measure": "12-lead ECG", 
                "safety_issue": "Yes", 
                "time_frame": "After 7 days of treatment"
            }, 
            {
                "description": "Number and percentages of subjects with arrhythmias ( e.g ventricular tachycardia, supra ventricular tachycardia,..)", 
                "measure": "24h ECG Holter", 
                "safety_issue": "Yes", 
                "time_frame": "After 7 days of treatment"
            }, 
            {
                "measure": "FEV1", 
                "safety_issue": "Yes", 
                "time_frame": "After 7 days of treatment"
            }, 
            {
                "measure": "Blood and urine Laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "After 7 days of treatment"
            }, 
            {
                "measure": "Body weight", 
                "safety_issue": "Yes", 
                "time_frame": "After 7 days of treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703052"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "AUC; Cmax and tmax; t\u00bd", 
            "measure": "Pharmacokinetics of CHF 6001 and its metabolite", 
            "safety_issue": "No", 
            "time_frame": "After 7 days of treatment"
        }, 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2012"
    }
}